Cargando…

New Frameworks to Assess Value of Cancer Care: Strengths and Limitations

Confronted with the different clinical impacts of different treatments, the rising cost of cancer care, and the financial burden of high drug prices, several influential professional organizations have developed models with which to assess the clinical benefit and value of cancer treatment regimens....

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnipper, Lowell E., Bastian, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2016
Materias:	Value in Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912372/ https://www.ncbi.nlm.nih.gov/pubmed/27245568 http://dx.doi.org/10.1634/theoncologist.2016-0177

Ejemplares similares

Value-Based Care in Lung Cancer
por: Eaton, Keith D., et al.
Publicado: (2016)

Value: The Next Frontier in Cancer Care
por: Goulart, Bernardo H.L.
Publicado: (2016)

Getting Past No in Cancer Care
por: Kolodziej, Michael
Publicado: (2016)

End‐of‐Life Care Matters: Palliative Cancer Care Results in Better Care and Lower Costs
por: Dalal, Shalini, et al.
Publicado: (2017)

Addressing Patients’ Priorities as a Strategy to Improve Value
por: Wong, Yu-Ning, et al.
Publicado: (2016)

Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions
por: Peppercorn, Jeffrey
Publicado: (2017)

A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?
por: Wollins, Dana S., et al.
Publicado: (2016)

Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World
por: Goldstein, Daniel A., et al.
Publicado: (2016)

Those Who Pay Have a Say: A View on Oncology Drug Pricing and Reimbursement
por: Newcomer, Lee N.
Publicado: (2016)

Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies
por: Garrison, Louis P, et al.
Publicado: (2021)

313 Biobehavioral predictors of dose-limiting toxicities of cancer therapy: Identification of areas for preventative intervention
por: Thornton, Clifton P., et al.
Publicado: (2022)

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A., et al.
Publicado: (2020)

The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2023)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

The effectiveness and value of aducanumab for Alzheimer’s disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Synnott, Patricia G, et al.
Publicado: (2021)

The effectiveness and value of novel treatments for cystic fibrosis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2021)

Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Atlas, Steven J, et al.
Publicado: (2023)

The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Pandey, Rajshree, et al.
Publicado: (2021)

The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2022)

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Fazioli, Katherine T., et al.
Publicado: (2020)

Commentary: Developing best-practice guidelines for the reporting of E-values
por: VanderWeele, Tyler J, et al.
Publicado: (2020)

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Lancaster, Victoria, et al.
Publicado: (2022)

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2022)

Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: McKenna, Avery, et al.
Publicado: (2023)

The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

Getting Unstuck: Challenges and Opportunities in Caring for Patients Experiencing Prolonged Hospitalization While Stable for Discharge
por: Meo, Nicholas, et al.
Publicado: (2020)

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Big data, observational research and P-value: a recipe for false-positive findings? A study of simulated and real prospective cohorts
por: Veronesi, Giovanni, et al.
Publicado: (2020)

Oral treatments for outpatient COVID-19: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of novel acute treatments for migraine: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

Unreasonable reasons: normative judgements in the assessment of mental capacity
por: Banner, Natalie F
Publicado: (2012)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

315 Development of a Mobile Software Application to Promote Education, Self-Care, and Treatment Follow-Up among Puerto Rican Breast Cancer Patients
por: Abreu, Jenniffer, et al.
Publicado: (2022)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ppm14t8d31tj8plgcc2ep03ipe